About this trial
Decreased respiratory function is a common side effect experienced by non-small cell lung cancer (NSCLC) patients who receive radiation therapy. In current clinical practice when treating cancerous lesions in the lung, it is not standard to explicitly try and avoid excessive radiation dose and therefore radiation injury to smaller airways. However, because of this patients may obtain damage to an airway segment can cause downstream regions in the lung to lose their "supply line" and, therefore, cause patients to lose the ability to exchange oxygen with the blood. The purpose of this clinical trial is to systematically compare post-treatment lung function of those who receive regular clinical radiation therapy (standard of care \[SoC\]) versus those who receive the airway-sparing radiation therapy regimen. The investigators hope to show that, by preserving airways and connected lung regions, participants will be able to retain a larger amount of their lung function, which will have a direct, positive impact on their post-treatment quality of life.
Eligibility criteria
Qualifiers
Step 1- Inclusion Criteria
Adult (≥18 years) patients (both sexes) with histologically diagnosed Stage III NSCLC per AJCC ver 9
Patients to be treated with definitive external beam photon radiotherapy with or without systemic therapy (e.g., chemothrapy, immunotherapy).
No restrictions on number radiotherapy fractions, or location/number of lesions
Disqualifiers
Step 1- Exclusion Criteria
Prior lung cancer-directed radiotherapy
Recent (< 12 mo) or planned lung surgery (which would confound pre- and post-RT lung function measures)
Patients with metal implants or metal stents in the thoracic region
Trial design
Treatments tested in this trial
- SOC Radiation Treatment Planning
- INSPIRE Radiation Treatment Planning
Treatment groups
Locations
1Sponsors and collaborators
University of Maryland, Baltimore
Lead sponsor